" "

Due to COVID-19, HCA’s lobby is closed until further notice. Learn more about your virtual customer service options.

Meetings and materials

The P&T Committee / DUR Board meet at least quarterly. All meetings are open to the public.

Meetings and materials: Pharmacy and Therapeutic (P&T) Committee/Drug Utilization Review (DUR) Board

Upcoming meetings

All 2022 P&T Committee meetings with be held by webinar until further notice.

February 16, 2022

April 20, 2022

June 15, 2022

August 17, 2022

October 19, 2022

December 14, 2022

Materials

Drug class reports will be taken down 30 days after the meeting.

Date General documents P&T Documents DUR documents

December 15, 2021

WEBINAR ONLY

Agenda (12/15/2021)

Recorded webinar (12/15/2021)

ADHD review postponed until Feb. 2022

Antidepressant report

Antidepressant motion

CGRP report

CGRP motion

 

HIV presentation

Drug class reviews

Drug class motions

Draft cabenuva policy

Draft evrysdi policy

Draft spinraza policy

Policy motions

October 20, 2021

WEBINAR ONLY

Agenda (10/20/2021)

Recorded webinar (10/20/2021)

Transcript (10/20/2021)

LAI motion

LAI archive motion

MS motion

Drug class reviews

Drug class motions

Draft antihyperlipidemics policy

Policy motion

Drug class addendum

August 18, 2021

WEBINAR ONLY

Agenda (08/18/2021)

Recorded webinar part 1

Recorded webinar part 2

Transcript (08/18/2021)

 

Drug class reviews

Drug class motions

Policy motions

Drug class addendum

Draft armodafinil, modafinil policy

Draft GLP-1 agonists policy

Draft serotonin modulators policy

June 16, 2021

WEBINAR ONLY

Agenda (06/16/2021)

Recorded webinar

Transcript (06/16/2021)

 

Drug class reviews

Drug class motions

Drug class addendum

Dupixent policy

Edurant policy

Eucrisa policy

Isotretinoin policy

Policy motions

April 21, 2021

WEBINAR ONLY

Agenda (04/21/2021)

Recorded webinar (04/21/2021)

Transcript (04/21/2021)

Asthma biologics motion

TIMs motion

Drug class reviews

Drug class motions

Drug class addendum

Evrysdi policy

Radicava policy

Spinraza policy

Imidazotetrazines policy

Policy motions

February 17, 2021

WEBINAR ONLY

Agenda (02/17/2021)

Recorded webinar (02/17/2021)

Transcript (02/17/2021)

 

Drug class addendum and list of archived classes

Drug class reviews

Pulmonary hypertension policy

Apple Health archived drug classes

Drug class motions

Pulmonary hypertension policy motion

Meeting details

  • All P&T Committee/DUR Board meetings are open to the public.
  • Stakeholders will be allowed three minutes for comments.
  • Written testimony: If you would like to give testimony, but cannot attend a meeting, please email a two-page maximum letter to the WPDP program at least one week before the meeting. She will put your testimony in the P&T Committee binders. If your testimony is longer than two pages, contact Leta for an address to mail it to. If you provide new drug information that has not been reviewed by the Drug Effectiveness Review Project (DERP), it cannot be considered by the committee.
  • Committee discussion and motions follow stakeholder comments.
  • If you have questions about the Apple Health PDL, please email the Apple Health pharmacy policy team.
  • Meetings are sponsored by the Health Care Authority and meet requirements of the Americans with Disabilities Act. Please call our ADA Coordinator at 360-725-9976 to make a request for special accommodations. TRS users may call this number through the Washington Relay Service by dialing 711.

Meetings held by webinar

If you would like to speak on any topic listed on the agenda, email the WPDP program, by the Monday before the meeting date:

  • Your name;
  • The organization you represent; and
  • The drug class name on the agenda.

The Committee Chair will call these names after the drug class presentation. You will be unmuted and have 3 minutes to speak. If you do not sign up ahead of time, but would like to speak at the meeting, the Committee Chair will ask if there are any other stakeholders. "Raise your hand", you will be unmuted when your name is called. You will have 3 minutes to speak. You can also ask questions in the "chat" box.

Meetings held at the Conference Center

  • Directions to The Conference Center in Sea-Tac airport.
  • Sign up at the meeting to testify on a drug class. Stakeholder sign-up sheets are located in the lobby.

Medicaid supplemental rebates

Effective January 1, 2018 HCA joined The Optimal PDL Solution (TOP$) supplemental rebate pool administered by Provider Synergies, a subsidiary of Magellan Medicaid Administration, LLC.

Please refer to the TOP$ website for more information about contracting and submitting rebates.

For additional Medicaid questions, please send an email to Apple Health (Medicaid).

Request archived materials

Email: PDP@hca.wa.gov

Stakeholder list

If you would like to receive P&T/DUR meeting agendas and drug class updates sign up for the Prescription Drug Program Stakeholder List.